- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04647409
Screening for NAFLD in Flanders
February 28, 2024 updated by: Geert Robaeys, Hasselt University
Screening for Non-Alcoholic Fatty Liver Disease (NAFLD) in a General Practitioner Population, in Flanders, Belgium.
In the Belgian adult population more than half, and numbers are still increasing, of the population is overweight or obese.
These people are at risk to develop NAFLD.
However, we lack epidemiological data in Belgium.
Therefore, it is important to do epidemiological studies to investigate NAFLD prevalence and disease severity based on a non-invasive approach and evaluate how patients are to be referred.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Geert Robaeys, prof. dr.
- Phone Number: +32 89 32 65 05
- Email: geert.robaeys@zol.be
Study Contact Backup
- Name: Leen Heyens, drs.
- Phone Number: +32 89 21 20 55
- Email: leen.heyens@uhasselt.be
Study Locations
-
-
-
Hasselt, Belgium, 3500
- Recruiting
- Hasselt University
-
Contact:
- Leen Heyens, drs.
- Phone Number: +32 89 21 20 55
- Email: leen.heyens@uhasselt.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18 years or older,
- able to understand Dutch,
- able to understand the informed consent
Exclusion Criteria:
- secondary causes of steatosis
- excessive alcohol abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: participants
|
The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CLDQ-NAFLD
Time Frame: baseline
|
The determination of the prevalence of NAFLD in a general population in Flanders, Belgium by using A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
|
baseline
|
36-Item Short Form Survey (SF-36)
Time Frame: baseline
|
SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
These measures rely upon patient self-reporting and are now widely utilized by managed care organizations and by Medicare for routine monitoring and assessment of care outcomes in adult patients.
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Leen Heyens, drs., Hasselt University
- Principal Investigator: Geert Robaeys, prof. dr., Hasselt University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2020
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
November 26, 2020
First Submitted That Met QC Criteria
November 26, 2020
First Posted (Actual)
November 30, 2020
Study Record Updates
Last Update Posted (Actual)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCREEFLAN-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on screening
-
Vastra Gotaland RegionRecruiting
-
University of FloridaPatient-Centered Outcomes Research InstituteEnrolling by invitation
-
Peking University People's HospitalSun Yat-sen University; Fudan University; Sun Yat-Sen Memorial Hospital of Sun... and other collaboratorsCompletedBreast Cancer | Bone MetastasesChina
-
National Institute of Allergy and Infectious Diseases...Ohio Department of Health, City of Cincinnati Board of HealthCompleted
-
University of British ColumbiaUniversity of SydneyRecruitingCardiovascular Diseases | End Stage Renal Disease | Kidney Transplantation | Dialysis Related ComplicationCanada, United States, United Kingdom, Germany
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
University of La LagunaCompletedHepatitis C Virus InfectionSpain
-
University of PittsburghNational Institute of Mental Health (NIMH); Kaiser Foundation Research InstituteCompleted
-
LMC Diabetes & Endocrinology Ltd.RecruitingType 2 Diabetes | Nonalcoholic SteatohepatitisCanada
-
University of La LagunaRecruiting